Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

CLEVELAND, Ohio – If you have eaten at a restaurant, stopped for a drink, sauntered through downtown streets or glanced up at a building in Cleveland, you are familiar with Bruce Farkas’ work ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

Managing email signatures across an entire organization can be a tedious and time-consuming task. Ensuring consistent branding, compliance, and professionalism in every employee’s email signature ...

Following the constitutional mandate, the case must now go to the Senate for trial. WITH 215 signatures, the House of Representatives on Wednesday impeached Vice President Sara Duterte ...

Eye­Point Phar­ma­ceu­ti­cals, a biotech at­tempt­ing to grab a sliv­er of Re­gen­eron’s share of the de­gen­er­a­tive eye dis­ease mar­ket, said six-month re­sults show its ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call.

Regeneron reported Q4 earnings on Tuesday, with revenues up 10% versus Q4 in 2023. EYLEA HD has stabilized its franchise with a modest sales growth of 1% in 2024 versus 2023. Biosimilar ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target of $950.00. The company’s shares closed ...

Credit: NASA/JPL-Caltech There is a perception that NASA’s Mars Sample Return (MSR) mission is being delayed by indecision, but the real delay has been multiple decades of seeking a heritage ...